Neumora Therapeutics (NMRA) News Today $1.56 -0.40 (-20.41%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.64 +0.09 (+5.45%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Neumora Therapeutics (NMRA) Expected to Announce Earnings on WednesdayJuly 30 at 4:16 AM | marketbeat.comMizuho Raises Price Target for Neumora (NMRA), Keeps Outperform RatingJuly 30 at 2:24 AM | msn.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from BrokeragesJuly 28, 2025 | americanbankingnews.comEdesa Biotech (NASDAQ:EDSA) vs. Neumora Therapeutics (NASDAQ:NMRA) Critical ReviewJuly 24, 2025 | americanbankingnews.comNeumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025July 23, 2025 | globenewswire.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by AnalystsJuly 21, 2025 | marketbeat.comMizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform RatingJuly 20, 2025 | finance.yahoo.comNeumora Therapeutics (NASDAQ:NMRA) Given New $5.00 Price Target at MizuhoJuly 16, 2025 | marketbeat.comNeumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861July 10, 2025 | finanznachrichten.deNeumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861July 9, 2025 | globenewswire.comWith 43% ownership, Neumora Therapeutics, Inc. (NASDAQ:NMRA) has piqued the interest of institutional investorsJuly 2, 2025 | finance.yahoo.comLunate Capital Ltd Acquires Shares of 2,124,143 Neumora Therapeutics, Inc. (NASDAQ:NMRA)June 29, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by AnalystsJune 26, 2025 | marketbeat.comNeumora Therapeutics Inc News (NMRA) - Investing.comJune 24, 2025 | investing.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Hold" by AnalystsJune 1, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmMay 27, 2025 | globenewswire.comNeumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug developmentMay 24, 2025 | uk.investing.comSoftbank Group CORP. Has $69.34 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)May 18, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of NMRA Q2 EarningsMay 17, 2025 | marketbeat.comQ2 EPS Forecast for Neumora Therapeutics Raised by AnalystMay 17, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MDMay 17, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)May 15, 2025 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Holdings Lessened by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPSMay 14, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmMay 14, 2025 | prnewswire.comNeumora Therapeutics, Inc.: Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finanznachrichten.deNeumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ...May 13, 2025 | finance.yahoo.comNeumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comNeumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comWill Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely?May 11, 2025 | finance.yahoo.comSchonfeld Strategic Advisors LLC Increases Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)May 5, 2025 | marketbeat.comNeumora Therapeutics (NMRA) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comNeumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025April 28, 2025 | globenewswire.comCapital International Investors Raises Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)April 23, 2025 | marketbeat.comKuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmApril 16, 2025 | investing.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by AnalystsApril 14, 2025 | marketbeat.comNeumora Therapeutics' (NMRA) "Buy" Rating Reaffirmed at Needham & Company LLCApril 12, 2025 | marketbeat.comNMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitApril 7, 2025 | globenewswire.comNeumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.April 7, 2025 | globenewswire.comNMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmApril 7, 2025 | businesswire.comNeumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law ...April 7, 2025 | gurufocus.comNeumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your Rights - NMRAApril 7, 2025 | prnewswire.comNMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRAApril 6, 2025 | globenewswire.comLevi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming DeadlineApril 6, 2025 | markets.businessinsider.comNMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action LawsuitApril 6, 2025 | globenewswire.comFaruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRAApril 6, 2025 | globenewswire.comNMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action LawsuitApril 5, 2025 | prnewswire.comNMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The FirmApril 4, 2025 | prnewswire.comNeumora Therapeutics' (NMRA) "Underperform" Rating Reaffirmed at Bank of AmericaApril 4, 2025 | marketbeat.comLevi & Korsinsky Reminds Neumora Therapeutics, Inc. ...April 4, 2025 | gurufocus.com Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address NMRA Media Mentions By Week NMRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMRA News Sentiment▼0.000.45▲Average Medical News Sentiment NMRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMRA Articles This Week▼38▲NMRA Articles Average Week Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Evotec News Today Edgewise Therapeutics News Today ANI Pharmaceuticals News Today Intellia Therapeutics News Today 89BIO News Today Vera Therapeutics News Today Biohaven News Today Cogent Biosciences News Today Travere Therapeutics News Today Harrow News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMRA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMRA Stock Alerts